All productsCagrilintide
Size
- 5 mg — $70.00 CAD — Available
- 10 mg — $130.00 CAD — Available
Research focus
A long-acting analogue of amylin, a pancreatic hormone involved in satiety signalling.
In simple words
Cagrilintide is a modified, long-acting version of amylin, a pancreatic hormone involved in fullness signals. Researchers study how amylin-like signalling relates to body weight.
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
Research references
Reviewed 2026-10-26
Human — randomized controlled trial
706 randomized adults with overweight or obesity, without diabetes.
The long-acting amylin analogue produced greater weight reductions than placebo in a 26-week study.
Treatment discontinuations included adverse events. This is not evidence for combining it with Retatrutide or Tesamorelin, or for the safety of this catalogue vial.
PMID 34798060. Indexed abstract checked through Europe PMC on 2026-10-26. Selected evidence, not a systematic review.
Resources
Compound name and formula checked via PubChem PUG REST. This reference does not verify the vial, salt or formulation.
PubChemMechanism and target search. Automated access returned 403; DrugBank was not used to substantiate claims or approval status.
DrugBankProtein/precursor search, not a record of the supplied vial. Synthetic compounds and lab supplies may have no matching protein entry.
UniProtBioactivity search. Assay results depend on the tested compound, target and experimental conditions.
ChEMBLExplore indexed literature. Search results are not supporting citations; selected verified publications appear above.
PubMedExplore registrations. A match or completed study does not establish efficacy, approval or relevance to this vial.
ClinicalTrials.govEvidence on studied compounds does not establish the identity, purity, safety, or regulatory approval of the catalogue vial. No Canadian regulatory status is assessed here.
Research questions about Cagrilintide
What is Cagrilintide?
Cagrilintide is a modified, long-acting version of amylin, a pancreatic hormone involved in fullness signals. Researchers study how amylin-like signalling relates to body weight.
What types of research are cited for Cagrilintide?
The Cagrilintide profile contains the following selected evidence. This is not a systematic review or a complete inventory of research.
Cagrilintide: dose-finding phase 2 trial (2021): Human — randomized controlled trial
Publication: Cagrilintide: dose-finding phase 2 trialWho or what was studied in the selected Cagrilintide references?
Cagrilintide: dose-finding phase 2 trial (2021): 706 randomized adults with overweight or obesity, without diabetes.
Publication: Cagrilintide: dose-finding phase 2 trialWhat identity distinctions matter for Cagrilintide?
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
What do the selected Cagrilintide studies not establish?
Cagrilintide: dose-finding phase 2 trial (2021): Treatment discontinuations included adverse events. This is not evidence for combining it with Retatrutide or Tesamorelin, or for the safety of this catalogue vial.
Publication: Cagrilintide: dose-finding phase 2 trialThese studies do not establish the identity, purity, safety or effects of the MXC Cagrilintide vial. Findings in one formulation, population or experimental model should not be assumed to apply to another.